nofazinlimab,lenvatinib
eqrx,cstone pharmaceuticals,eisai pharmaceutical
['hcc', 'nofazinlimab']
csstone presents updated anti-pd-1 antibody results nofazinlimab in combination with lenvatinib as first-line therapy in patients with non-resectable hepatocellular carcinoma (hcc) at asco 2022, business news 